Inspiring to see the added value that bispecific antibodies can bring to patients with #unmetmedicalneed @BioconBiologics @kiranshaw
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
RT @ChristianRolfo: Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, i…
@CD_AACR @ElizSMcKenna @isliquidbiopsy @CHematology
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
Very nice paper in this hot topic: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC https://t.co/s1gFoKIQSP @lcsmchat @EGFRResisters @EgfrUk @LUNGevity @lcrf_org @da
RT @VivekSubbiah: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Inse…
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC @CD_AACR https://t.co/PrtXLcfZgK
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC https://t.co/e4QZPPNdxg
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC | Cancer Discovery https://t.co/vLvfDRs0uv
RT @CD_AACR: From the August issue: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20…
RT @CD_AACR: From the August issue: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20…
From the August issue: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC https://t.co/Z5tYB6TMoP https://t.co/BmDMADkenC
RT @CD_AACR: #ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driv…
RT @ChristianRolfo: @lcsmchat @EGFRResisters @EgfrUk @OncoAlert @IASLC
@lcsmchat @EGFRResisters @EgfrUk @OncoAlert @IASLC
RT @CD_AACR: #ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driv…
RT @CD_AACR: #ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driv…
RT @CD_AACR: #ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC #WLCD2020 https://t.co/Y3Ea3Bhslg https://t.co/VIv7UVl6tY
#ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC #WLCD2020 https://t.co/dlIgK7H3Cg https://t.co/FOt90mPhTj
RT @ElizSMcKenna: Read the recent @CD_AACR publication related to this #AACR20 poster and FDA Breakthrough Therapy here: https://t.co/9CnrY…
RT @ElizSMcKenna: Read the recent @CD_AACR publication related to this #AACR20 poster and FDA Breakthrough Therapy here: https://t.co/9CnrY…
RT @ElizSMcKenna: Read the recent @CD_AACR publication related to this #AACR20 poster and FDA Breakthrough Therapy here: https://t.co/9CnrY…
Read the recent @CD_AACR publication related to this #AACR20 poster and FDA Breakthrough Therapy here: https://t.co/9CnrY1STd4
RT @osoegawa_ths: Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon … http…
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon … https://t.co/7VyInCCAhC
RT @ElizSMcKenna: Related to #ASCO20 abstract 9512: https://t.co/tFg0p7dN3M
RT @ElizSMcKenna: Related to #ASCO20 abstract 9512: https://t.co/tFg0p7dN3M
Antitumor Activity of an EGFR-cMet Bispecific Antibody in EGFR Exon 20 Insertion-Driven NSCLC. Both EGFR signaling inhibition and ADCC as mechanisms of action. https://t.co/iXFb59RDuk
RT @ElizSMcKenna: Related to #ASCO20 abstract 9512: https://t.co/tFg0p7dN3M
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
Related to #ASCO20 abstract 9512: https://t.co/tFg0p7dN3M
ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC https://t.co/7V7Nq2Ajl6 https://t.co/0DGa2fyagO
RT @ElizSMcKenna: ICYMI in @CD_AACR: Preclinical and initial clinical antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispec…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Preclinical and initial clinical antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispec…
RT @ChristianRolfo: @lcsmchat @OncoAlert
RT @ElizSMcKenna: ICYMI in @CD_AACR: Preclinical and initial clinical antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispec…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Preclinical and initial clinical antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispec…
@lcsmchat @OncoAlert
RT @ElizSMcKenna: ICYMI in @CD_AACR: Preclinical and initial clinical antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispec…
ICYMI in @CD_AACR: Preclinical and initial clinical antitumor activity of amivantamab (JNJ-61186372), an EGFR-cMet bispecific antibody, in #EGFR ex20 #NSCLC (related to #ASCO20 Abstract 9512 on ongoing CHRYSALIS phase I results) https://t.co/NzGpODE3j6
RT @organoidscience: Published in @CD_AACR! 👨🔬 Researchers used patient-derived #organoids harboring diverse Exon20ins to characterize th…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
Published in @CD_AACR! 👨🔬 Researchers used patient-derived #organoids harboring diverse Exon20ins to characterize the anti-tumor mechanism of amivantamab. https://t.co/XsfF5g2yPK https://t.co/AHmw7mkcdm
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @CD_AACR: Just published #OnlineFirst! Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR e…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
RT @CD_AACR: ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–drive…
ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC https://t.co/29y6JpP4Xu https://t.co/wyEiL4DJZ5
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @ElizSMcKenna: Now online in @CD_AACR: another agent with potential activity in EGFR exon 20 NSCLC - follows amivantamab's Breakthrough…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…